Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 39 - General protective or antinoxious agents
Patents for A61P 39 - General protective or antinoxious agents (19,019)
04/2003
04/02/2003EP1296929A2 Modified forms of pharmacologically active agents and uses therefor
04/02/2003EP1296699A1 Therapeutic agents - iii
04/02/2003EP1296698A1 Therapeutic agents - ii
04/02/2003EP1296697A1 Therapeutic agents - i
04/02/2003EP1296639A1 Cosmetic and pharmaceutical compositions and methods using green-light emitting materials
04/02/2003EP1208100B1 Selective antagonists of a2b adenosine receptors
04/02/2003EP0993304B1 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative
04/02/2003EP0770081B1 Heterocycle-condensed morphinoid derivatives
04/02/2003CN1407900A Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1)
04/01/2003US6541638 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction
04/01/2003US6541623 Sepsis shock therapy; rheumatic diseases; antiinflammatory agents; nucleotide sequence detector
04/01/2003US6541503 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
04/01/2003US6541490 Treating ischemia or reoxygenation injury; preparation from a bipyridine, a benzeneboronic acid and a manganese salt
04/01/2003US6541230 Using polyurethane, cholinesterases, and reactivation compounds; efficiency
03/2003
03/27/2003WO2003024940A1 Bifunctional chelating agent for actinium
03/27/2003WO2003024487A1 Method of increasing the presence of glutathione in cells
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002094019A9 Highly purified antiendotoxin compound
03/27/2003US20030060505 Administration of a radioprotective alpha, beta unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces cytotoxic side effects of radiation on normal cells
03/27/2003US20030059462 Dissolving a powder of liposome-forming lipids in an organic solvent to a level close to saturation, adding to the solute obtained a dry, water immiscible carotenoid to obtain a suspension, drying and dehydrating the powder obtained
03/27/2003CA2459547A1 Method of increasing the presence of glutathione in cells
03/26/2003EP1294882A2 B7-like molecules and uses thereof
03/26/2003EP1294849A1 Micro-organisms active in the digestive environment
03/26/2003EP1294765A2 Il-17 molecules and uses thereof
03/26/2003EP1294750A2 Acid-modified arabinogalactan protein composition
03/26/2003EP1294395A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR VIIa INHIBITOR
03/26/2003EP1294369A1 NOVEL FORMULATIONS OF $g(a)-2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONE
03/26/2003EP1140195B1 Oil-in-water emulsion exhibiting a protective action against damages to human organs resulting from peroxidation, and the production and use thereof
03/26/2003EP1098631B1 Pharmaceutical composition in particular for preventing and treating mucositis induced by radiotherapy or chemotherapy
03/26/2003EP0998477B1 Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents
03/26/2003CN1406280A Progenitor cell preservation factors and related methods and products
03/26/2003CN1406227A Aryl fused azapolycy clic compounds
03/26/2003CN1103597C Snake venom ointment and its preparation
03/26/2003CN1103588C Calcium complex of 4-(4-ethoxybenzyl)-3,6,9-tris (carboxylatomethyl)-3,6,9-triazaundecanedioic acid and its salt, pharmaceutical agents containing these complexes
03/25/2003US6538036 Method for preventing and treating peripheral neuropathy by administering selegiline
03/25/2003US6538021 Method for producing luteolin and luteolin derivatives
03/25/2003US6538019 Produce emulsions containing a material that are insoluble or that have low solubility with respect to water and oil in a high concentration, so as to obtain emulsions which can be preserved for a long period of time. More specifically,
03/20/2003WO2003022246A1 Treating effects of excessive reactive oxygen species
03/20/2003WO2003022218A2 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
03/20/2003WO2003022217A2 Treatment of excessive radiation (e.g. sunburn) exposure
03/20/2003WO2002092077A3 Use of lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
03/20/2003WO2002067865A3 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
03/20/2003WO2002050255A3 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
03/20/2003US20030055260 Il-8 receptor antagonists
03/20/2003US20030055098 Method of treatment
03/20/2003US20030055032 For therapy or inhibiting the development of a pathology associated with peroxynitrite damage
03/20/2003US20030055021 Compounds for the treatment of ischemia
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054014 Administering fungi spores; aging resistance
03/20/2003US20030054000 Anti-pathogen system and methods of use thereof
03/20/2003US20030053967 Use of 3,4-dihydroxy-mandelic acid for protecting against oxidative damage caused by ultra-violet light
03/19/2003EP1292683A2 Secreted redox proteins
03/19/2003EP1292608A2 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
03/19/2003EP1292324A2 Critical illness neuropathy
03/19/2003EP1292288A2 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
03/19/2003EP0657520B1 Antioxidant
03/19/2003CN1404471A Substituted piperazine compounds
03/19/2003CN1404395A Antiadhesive carbohydrates
03/19/2003CN1404387A Cosmetic preparations containing plant extracts
03/18/2003CA2360311C Improved dialysis solutions and methods
03/13/2003WO2003020949A2 Targeted nucleic acid constructs and uses related thereto
03/13/2003WO2003020700A2 SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF
03/13/2003WO2003020291A1 Increased solubility flavanolignan preparations
03/13/2003WO2003020257A2 USE OF β-ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
03/13/2003WO2003020254A1 Pharmaceutical composition comprising (-)-secoisolariciresinol
03/13/2003WO2002074343A3 The use of non-digestible polymeric foams to sequester ingested materials, thereby inhibiting their absorption by the body
03/13/2003US20030050345 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroximic acid derivative
03/13/2003US20030050298 A sulfonamide substituted diphenyl thiourea compounds treating a chemokine mediated disease
03/13/2003US20030050281 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
03/13/2003US20030050234 Conotoxin peptide extracted from the venom of a marine snail, Conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics
03/13/2003US20030049287 Catechol oximes and their use in cosmetic and dermatological preparations
03/13/2003US20030049279 Polysaccharide encapsualted antigen
03/13/2003US20030049226 Methods of treating syndrome x with aliphatic polyamines
03/13/2003US20030049203 Targeted nucleic acid constructs and uses related thereto
03/13/2003CA2458963A1 Increased solubility flavanolignan preparations
03/13/2003CA2458780A1 Targeted nucleic acid constructs and uses related thereto
03/13/2003CA2457534A1 Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
03/12/2003EP1291346A1 Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties
03/12/2003EP1290187A2 Humain kinases
03/12/2003EP1290180A2 Drug metabolizing enzymes
03/12/2003EP1289556A2 Phytoestrogenic isoflavone compositions
03/12/2003EP1289518A2 Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
03/12/2003CN1402718A Neutralizing agent for toxin of microorganism belonging to genus clostridium
03/11/2003WO2002022578A1 (2-azabicyclo[2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
03/11/2003CA2421936A1 (2-azabicyclo[2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
03/11/2003CA2346647C Treatment of dyspepsia
03/06/2003WO2003018606A2 Casein derived peptides and uses thereof in therapy
03/06/2003WO2003018579A1 Alkyne-aryl phosphodiesterase-4 inhibitors
03/06/2003US20030045574 Such as alpha-phenyl-N-(7-tert-butoxycarbonylamino-3,5-dimethyladamantane)nitrone for treatment of neurological/ inflammatory diorders, and aging, which result from the overproduction of nitric oxide
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045461 Composition and methods of esterified nitroxides gated with carboxylic acids
03/06/2003US20030044888 Polypeptide for use in the treatment of addison's disease
03/06/2003US20030044424 Novel immune enhancing compositions
03/06/2003CA2458924A1 Casein derived peptides and uses thereof in therapy
03/05/2003EP1288203A1 Cyclic nitrones and pharmaceutical compositions containing them
03/05/2003EP1286986A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
03/05/2003EP1169316B1 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
03/05/2003EP0853610B1 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
03/05/2003EP0690863B1 Tetracyclic compounds as dopamine agonists
03/05/2003CN1399962A Pralidoxime chloride powder injection and its preparation method
1 ... 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 ... 191